Market News
Recent Developments
New product launches and research and development activities
- On October 2, 2023, Stanford University in collaboration with Kite Pharma, a pharmaceutical company, started a clinical trial for the safety and efficacy of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia. The study is expected to be completed in August 2025.
- On August 17, 2023, Bristol Myers Squibb Company, a biopharmaceutical company, announced that the Japanese regulatory approval for an authorized generic (AG) version of its tyrosine kinase inhibitor Sprycel (dasatinib)
- In April 2020, Reddy’s Laboratories Ltd., a pharmaceutical company, announced the launch of Invista, a formulation of Dasatinib in India. It is indicated for the treatment of chronic accelerated or myeloid or lymphoid blast phase and newly diagnosed in chronic phase adult patients with Chronic Myeloid Leukemia (CML) in India.
Partnership and Acquisition
- In January 2020, St. Jude Children’s Research Hospital and the Chinese Children’s Cancer Group announced a partnership first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome. Results showed that the drug dasatinib provides more benefit than the standard of care, which led to changes in the way this leukemia is treated
U.S.: 
U.K. : 
India : 
